European dermatology forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis
Robert Knobler(Medical University of Vienna), Thomas Krieg(University of Cologne), Ivan Foeldvari(Center for Rheumatology), Vanessa Smith(Ghent University Hospital), Jaana Panelius(University of Helsinki), Michael Sticherling(Universitätsklinikum Erlangen), Maurizio Cutolo(Ospedale Policlinico San Martino), C. Françès(Navarre Institute of Health Research), Cord Sunderkötter(MSB Medical School Berlin), G. Bali(Semmelweis University), Veli‐Matti Kähäri(University of Turku), Alain Taı̈eb(Université de Bordeaux), Ahmad Jalili(Medical University of Vienna), L.A. Frasin(Alessandro Manzoni Hospital), Margitta Worm(Charité - Universitätsmedizin Berlin), Ulrike Just(University Hospital Heidelberg), Dorota Krasowska(Medical University of Lublin), Lidia Rudnicka(Medical University of Warsaw), Peter Wolf(University Hospital Heidelberg), Pietro Quaglino(Department of Medical Sciences), Anna Skrok(Medical University of Warsaw), M. Bagot(Inserm), Adrian Tanew(Universitätszahnklinik Wien), Pia Moinzadeh(University of Cologne), Klaus F. Kofoed(University of Copenhagen), Annamari Ranki(University of Helsinki), Jean‐David Bouaziz(Université Paris Cité), Małgorzata Olszewska(Medical University of Warsaw), Julien Sénéschal(Hôpital Saint-André), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Franco Rongioletti(Vita-Salute San Raffaele University), Elisabeth Aberer(Medical University of Graz), Aurora Parodi(Ospedale Policlinico San Martino), Armando Gabrielli(Marche Polytechnic University), Anne Braae Olesen(Aarhus University Hospital), A. Petit(Hôpital Saint-Louis), Antonio Cozzio(Ostschweizer Kinderspital), N. Hunzelmann(University Hospital Cologne), Nora Wutte(Medical University of Graz), Chris Denton(Tissue Dynamics (Israel)), J Schmidt(FH Münster), Luc Mouthon(Université Paris Cité), Catherine H. Orteu(Royal Free London NHS Foundation Trust), Sarolta Kárpáti(Semmelweis University)
Cited by 115
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k